Company Information

  

Address: 88 SIDNEY STREET  
City: CAMBRIDGE 
State: MA 
Zip Code: 02139 
Telephone: 617-649-8600 

Description of Business

Primary SIC Code: 2834
(As filed with the SEC)  

We are a biopharmaceutical company committed to the fundamental transformation of patients' lives through scientific leadership in the fields of cancer and rare genetic metabolic disorders. We have built a unique set of core capabilities in the field of cellular metabolism, with the goal of making transformative, first- or best-in-class medicines. Our therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a broad group of more than 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. In both of these areas, we are seeking to unlock the biology of cellular metabolism as a platform to create transformative therapies. Our most advanced cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 and 1, or IDH2 and IDH1, respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.  ... More ...  

Per Share Overview

Date 12-mos Rolling EPS Dividend P/E Ratio
06/2017-6.53NAN/E
03/2017-6.02NAN/E
12/2016-5.07NAN/E
09/2016-4.81NAN/E
06/2016-4.25NAN/E
03/2016-3.63NAN/E
12/2015-3.15NAN/E
09/2015-2.84NAN/E

Key Financial Ratios and Statistics

FYE: 12/31

Profitability 2016 Leverage 2016
Net Inc/Comm Equity-0.24Total Liab/Total Assets0.42
Net Inc/Total Assets-0.32Total Liab/Inv Cap0.49
Net Inc/Inv Cap-0.37Total Liab/Comm Equity0.31
Pretax Inc/Net Sales-2.84Interest Coverage RatioNA
Net Inc/Net Sales-2.84Curr Debt/EquityNA
Cash Flow/Net Sales0.55LTD/EquityNA
SG&A/NetSales0.73Total Debt/EquityNA
Asset Utilization   Liquidity  
Net Receivables Turnover7.02Quick Ratio6.33
Inventory TurnoverNACurrent Ratio6.33
Inventory Day SalesNANet Rec/Curr Assets0.01
Net Sales/Work Cap0.15Inv/Curr AssetsNA
Net Sales/PP&E2.76  

Income Statement (Millions)

  6/30/2017 3/31/2017 12/31/2016 9/30/2016
Total Revenues(Net Sales) 11.35 10.51 22.65 8.99
Cost of Goods Sold NA NA NA NA
Selling & Admin Exps 16.13 14.82 15.38 11.85
Operating Income -84.60 -67.05 -57.41 -63.51
Interest Exp NA NA NA NA
Pretax Income -83.08 -66.17 -56.49 -62.83
Other Income 1.52 0.88 0.92 0.68
Net Income Bef Extraordinary ... NA NA NA NA
Net Income -83.08 -66.17 -56.49 -62.83

Balance Sheet (Millions)

Assets 6/30/2017 3/31/2017 12/31/2016 9/30/2016
Cash & Short Term Investments 586.04 479.76 541.31 579.10
Receivables - Total 5.62 14.72 8.31 11.57
Inventories - Total NA NA NA NA
Total Current Assets 604.68 506.87 559.89 600.94
Net Property, Plant & Equipment 24.77 24.14 25.34 26.26
Total Assets 760.60 557.32 619.09 672.04
Liabilities        
Accounts Payable 53.05 41.27 49.11 38.23
Debt in Current Liabilities NA NA NA NA
Total Current Liabilities 93.65 82.43 88.43 78.00
Long-Term Debt NA NA NA NA
Total Liabilities 251.61 249.94 260.50 270.59
Stockholder's Equity        
Minority Interest NA NA NA NA
Preferred Stock 0.00 0.00 0.00 0.00
Common Stock 0.05 0.04 0.04 0.04
Retained Earnings -632.64 -549.56 -483.15 -426.67
Treasury Stock NA NA NA NA
Total Stockholders' Equity 508.99 307.38 358.59 401.45
Total Liabilities and Stockholders' Equity 760.60 557.32 619.09 672.04

Cash Flow Summary (Millions)

Categories 6/30/2017 3/31/2017 12/31/2016 9/30/2016
Net Cash Provided by Operating Activities -58.99 -74.07 -51.22 -49.03
Net Cash Provided by Investing Activities -275.73 109.55 -77.52 -62.74
Net Cash Provided by Financing Activities 273.15 4.05 3.99 163.23

Annual Summary Data (Millions)

Year Sales Net Income EPS
12/201225.11-20.10--
12/201325.55-39.41-2.83
12/201465.36-53.50-1.59
12/201559.12-117.73-3.15
12/201669.89-198.47-5.07
Growth Rates29.17----

Stock Ownership

Type Date(Q,M) No. Owners Shares Held (000s) % Own
Institutional09/30/1718446,00495.07




Report Date : 10/16/2017

Powered By Edgar Online © 2017EDGAR®Online, a division of Donnelley Financial Solutions. EDGAR® is a federally registered trademark of the U.S. Securities and Exchange Commission. EDGAR Online is not affiliated with or approved by the U.S. Securities and Exchange Commission.